Sort
48,018 grants matching “immunotherapy”
Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core
$369,017Gatien Moriceau · University Of California Los Angeles · P01 · FY2024 · CA
Role of sub-activation-threshold TCR interactions in maintaining T cell memory
$369,015Nevil John Singh · University Of Maryland Baltimore · R01 · FY2016 · AI
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
$369,009Aimee S Payne · University Of Pennsylvania · R01 · FY2024 · AR
Marrow Infiltrating Lymphocyte Immunotherapy in Myeloma
$369,000Ivan M Borrello · Johns Hopkins University · R21 · FY2009 · CA
Marrow Infiltrating Lymphocyte Immunotherapy in Myeloma
$369,000Ivan M Borrello · Johns Hopkins University · R21 · FY2008 · CA
Integrating Low-Cost Paper-Based Devices and Personalized Immunotherapeutics to Treat Triple Negative Breast Cancer
$368,987Brian Richard McNaughton · Delaware State University · U54 · FY2024 · MD
Mechanisms and consequences of iNKT cell anergy
$368,968Luc Van Kaer · Vanderbilt University · R01 · FY2011 · AI
Establishing a clinical research flow cytometry core
$368,962Kaska Wloka · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Core 1: Biospecimen and Data Management Core
$368,934John B Sunwoo · Stanford University · U54 · FY2016 · CA
Adenovirus as a Vector for Gene Therapy
$368,918Patrick Hearing · State University New York Stony Brook · R01 · FY2011 · AI
Scientific Core B
$368,900Holden T. Maecker · Stanford University · U19 · FY2014 · AI
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$368,899Jinming Gao · Ut Southwestern Medical Center · R01 · FY2022 · CA
Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma
$368,862Jessie Villanueva · Wistar Institute · U54 · FY2025 · CA
Biomaterials Approach to Expand Hematopoietic Cells ex vivo
$368,773Kam W Leong · Duke University · R01 · FY2006 · HL
Exploiting dual-TCR for rescue of CD8 T cell tolerance in adoptive immunotherapy
$368,750Ryan M Teague · Saint Louis University · R01 · FY2010 · AI
IL12 AS AN IMMUNOPOTENTIATOR IN LEISHMANIASIS
$368,737University Of Pennsylvania · R01 · FY2000 · AI
Image-guided Interventional Combination Liver Cancer Immunotherapy
$368,722Zhuoli Zhang · University Of California-Irvine · R01 · FY2021 · CA
NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
$368,686Scripps Research Institute · U01 · FY2003 · AI
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells
$368,628Chrystal Mary Paulos · Emory University · R01 · FY2020 · CA
Recognition of bacterial antigens by NKT cells
$368,592Mitchell Kronenberg · La Jolla Institute For Immunology · R01 · FY2007 · AI
Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapy
$368,579Kun Cheng · University Of Missouri Kansas City · R01 · FY2023 · CA
IMMUNOREGULATION IN SCHISTOSOMIASIS
$368,566Tufts University Boston · R01 · FY2004 · AI
Mechanisms of EAE
$368,559Claude Paul Genain · California Pacific Med Ctr Res Institute · R01 · FY2006 · AI
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy
$368,487Yong Lu · Methodist Hospital Research Institute · R37 · FY2022 · CA
Developmental Funds
$368,469Steven K. Libutti · Rutgers Biomedical And Health Sciences · P30 · FY2023 · CA